Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 4;147(11):867–876. doi: 10.1161/CIRCULATIONAHA.122.061025

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 American Heart Association, Inc.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. — Humoral responses. Humoral responses of adolescents and young adults with postvaccine myocarditis (n=10) compared with age-matched postvaccine control subjects (n=17). A and B, Immunoglobulin (Ig) M/G/A to spike and RBD (receptor binding protein); (C) Fc receptors to Spike; (D) antibody-dependent complement deposition (ADCD), neutrophil phagocytosis (ADNP), and cellular phagocytosis (ADCP); (E) correlation heat map; (F) phage immunoprecipitation sequencing; and (G) heat map of VirScan. A through E include only samples that were collected within 11 days after the second vaccination dose to allow time-equivalent comparison of severe respiratory syndrome coronavirus disease 2 (SARS-CoV-2)–specific responses. F and G include 5 individuals with postvaccine myocarditis and 7 healthy vaccinated control subjects. Analysis by Mann-Whitney U map. *P<0.5. **P<0.01. ***P<0.001. ****P<0.0001.